A New Targeted Treatment for HER2-positive Breast Cancer
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted...
Progress Against Cancer
The FDA approved a new treatment for adults with advanced breast cancer that has developed resistance to other targeted...
While most primary cancer diagnoses have no standard of care for brain metastasis screening, a study published in Cancer...
A study found that African American and Hispanic women in Chicago were exposed to higher levels of ambient toxic...
The molecularly targeted therapeutic alpelisib was approved for certain patients who have advanced or metastatic breast cancer. The U.S....
The FDA approval is for the use of atezolizumab in combination with Abraxane for the treatment of certain patients...
Understanding risk could influence screening, surveillance practices Thanks to significant progress against cancer, there are now 16.9 million people...
The FDA approval of talazoparib means there are now two PARP inhibitors that can be used to treat patients...
Following dietary recommendations may reduce THE risk of several cancers. More vegetables and fruit. Less alcohol and processed food....
A recent study found that women who work the night shift may have an increased risk of breast, skin,...
The FDA has approved the molecularly targeted therapeutic olaparib for treating patients who have HER2-negative breast cancer and who...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 44,000 members worldwide drive progress against cancer.
Donate Today